These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23189850)

  • 41. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
    Cheng CH; Lin CC; Chen HL; Lin IT; Wu CH; Lee YK; Wong MW; Bair MJ
    Kaohsiung J Med Sci; 2017 Oct; 33(10):510-515. PubMed ID: 28962822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.
    Fathy MM; Abo Taleb ME; El Hawary MS; Nabih MI; Aref WM; Makhlouf MM
    Cytokine; 2015 Aug; 74(2):268-72. PubMed ID: 26003758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China.
    Li Y; Wang J; Wang J; Xiao Y; Xu B; Li H; Yang L; Hao X; Ma Y
    Virol J; 2017 Mar; 14(1):62. PubMed ID: 28335783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy.
    Shaker OG; Sadik NA
    J Gastroenterol Hepatol; 2012 Dec; 27(12):1842-9. PubMed ID: 23020144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epstein-Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients.
    Zekri AR; Abdullah D; Osman A; El-Rouby MN; Zayed N; Esmat G; Elakel W; Hafez HA
    Arab J Gastroenterol; 2015; 16(3-4):84-9. PubMed ID: 26526510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.
    Nadia K; Hicham E; Reda TM; Nadia T; Elarbi B; Saâd E; Mimoun Z; Saâd M
    Gene; 2015 Aug; 568(1):31-4. PubMed ID: 25958342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.
    Luo Y; Jin C; Ling Z; Mou X; Zhang Q; Xiang C
    Gene; 2013 Jan; 513(2):292-6. PubMed ID: 23142377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.
    López-Rodríguez R; Hernández-Bartolomé Á; Borque MJ; Rodríguez-Muñoz Y; Martín-Vílchez S; Trapero-Marugán M; García-Buey L; Muñoz de Rueda P; Rodrigo L; Vidal-Castiñeira JR; Salmerón J; Moreno-Otero R; Sanz-Cameno P
    Genes Immun; 2013; 14(5):317-24. PubMed ID: 23615070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
    Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
    Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.
    Palenzuela Gardón D; Guillen IA; Fernández JR; Camacho H; Estevez ZC; Dueñas S; Alvares-Lajonchere L; Amador Y; Martinez-Donato G; Han J; Zhang Z; Zhang X; Gao Y; Campaña JR; Novoa LI
    J Biomol Tech; 2017 Jul; 28(2):80-86. PubMed ID: 28058039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.